BII’s €9.52M Venture Programme Backs 17 Research-Based Startups

BioInnovation Institute (BII) has selected 17 research-based startups for its September 2026 Venture Programme, committing €9.52 million in convertible loans, or €560,000 per company. The announcement is as much about building companies around advanced research as it is about financing them: each venture is also set to receive access to BII’s innovation platform and support network. 1

What the selected companies receive

The programme combines early-stage capital with the practical infrastructure science-led companies often need before they can attract larger external rounds. Participants are expected to gain access to BII’s Copenhagen facilities and laboratory environment, as well as business expertise and an international investor network. 14

That approach aligns with BII Venture Lab’s wider model: pairing funding, knowledge, infrastructure and networks with scientific maturation, team development and entrepreneurial training. 4 BII also offers office and laboratory space to startups, underscoring the importance it places on physical infrastructure alongside capital. 31

The €560,000 investment is a convertible loan, meaning the financing is structured as debt that may later convert into equity rather than a conventional priced equity round. 13

Why the announcement matters

Research ventures—particularly those originating in university, hospital and deep-tech settings—face a demanding transition from a promising scientific result to a product, regulatory pathway, operating team and commercially viable business. BII’s programme is intended to address those early technical and commercial risks through capital and hands-on venture support. 4

The new cohort follows a reported €736 million commitment from the Novo Nordisk Foundation. Reporting on the initiative says the backing is intended to expand BII’s activity across Denmark and Europe, lift annual company support from roughly 20 to 30 startups, and extend its reach through partnerships. 714

The 17 startups and their focus areas

The cohort covers a wide range of life-science and deep-tech applications. The following technology descriptions reflect the announcement summary; available source excerpts independently confirm the cohort’s funding, broad sector range and support package, but do not substantiate every individual company description in detail. 114

Health, therapeutics and medical technology

• Sylvia Health — Less-invasive women’s pelvic-floor and reproductive-health medtech, initially focused on rectocele and pelvic-organ prolapse.
• Corcellys Therapeutics — Regenerative cell therapies for diseases of the eye surface.
• Alvara Therapeutics — Small-molecule treatments for chronic kidney disease.
• Epimass — Real-time mass-spectrometry analysis of surgical smoke and airborne particles, with potential use in faster intraoperative cancer diagnosis.
• IQopta — AI-enabled medical-imaging workflow technology for drug development and clinical trials.
• Affinity AI — AI-designed protein binders for drug development, diagnostics and biomedical research.
• Aperio Therapeutics — Long-acting biological treatments for energy-deficiency and cellular-signalling diseases related to metabolic physiology.

Climate, industrial technology and food

• Fibernex — 3D porous nanofibre electrodes intended to make green-hydrogen production more efficient while reducing nickel use.
• KhaosGuard — Mid-infrared open-path laser systems for real-time measurement of methane, nitrous oxide, carbon dioxide and other industrial greenhouse-gas emissions. 3
• Launch Bioindustries — Fermentation-based conversion of organic waste into sustainable biomaterials, including bioplastics.
• React Foods — Food-grade yeast proteins produced from carbon dioxide and renewable energy.
• PureSurf — Renewable, bio-based surfactants for chemical-industry applications.
• Reformable — Catalysts, modular reactors and processes designed to convert methane and carbon dioxide into syngas for fuels and chemicals.

AI, photonics and advanced hardware

• Human Thinking — Educational AI agents and learning systems aimed at helping students develop critical thinking.
• Lucore Technology — Photonic hardware designed for faster, more energy-efficient AI computing.
• Copenhagen Microsystems — 3D Ice Lithography equipment for sub-50-nanometre, three-dimensional micro- and nanostructures.
• Lizard Photonics — Integrated nanoelectromechanical photonics for compact, energy-efficient chip-level light control in data centres, AI, quantum technology and advanced sensors.

The larger takeaway

BII’s announcement signals an effort to make commercialization support more available to science-intensive startups at the point where laboratory progress must become a credible company. The 17 ventures are working in sectors with long development cycles and substantial technical risk, from regenerative medicine and industrial emissions monitoring to photonic computing hardware.

For the selected founders, the value proposition is therefore broader than the €560,000 loan: access to laboratories, commercial and scientific guidance, team development, fundraising support and investor connections may help close the gap between research validation and a business that can scale internationally. 414